ArticleThe oncologist2025
Comparison of lobectomy vs total thyroidectomy for medullary thyroid carcinoma: a SEER analysis with Chinese cohort validation.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to clarify whether lobectomy provides survival benefits for patients with early-stage medullary thyroid carcinoma (MTC). DESIGN, SETTING, AND
participantsPatients with tumor size less than 4 cm, excluding those with lateral neck involvement, bilateral foci, extrathyroidal extension, or distant metastases, were enrolled from the Surveillance, Epidemiology, and End Results (SEER) database and Zhejiang Cancer Hospital in China. Propensity score matching (PSM), Kaplan-Meier analysis, and Cox regression analyses were used to evaluate treatment outcomes and identify risk factors.
resultsAmong 1009 patients in the SEER database, TT was associated with multifocality (P < .001) and local nodal metastasis (P < .001). After PSM, 73 pairs were matched. In the Chinese cohort from Zhejiang Cancer Hospital, TT was correlated with larger tumor (P < .001), higher calcitonin peak-to-basal ratio (P = .002), and T2 stage (P = .025), with 38 matched pairs after PSM. Cox regression analyses showed that the extent of thyroid resection was not an independent prognostic factor for overall survival (SEER: OS P = .607) or progression-free survival (Chinese cohort: PFS P = .411). Kaplan-Meier analysis revealed no significant survival differences between the TT and lobectomy groups (SEER: OS P = .43; Chinese cohort: PFS P = .21). Additionally, the TT group had more frequent adverse events (transient hypocalcemia: P < .001, transient vocal cord paralysis: P < .025), longer hospital stays (P = .011), and higher costs (P = .001) than the lobectomy group.
conclusionsFor patients with early-stage MTC, lobectomy may be an optimal alternative option that does not impair prognosis and confers a low risk of adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.